Novo upon billion-dollar bid: An acquisition of Ablynx will not satisfy our hunger
Novo Nordisk is currently offering billions in the attempt to acquire the Belgian biotech company Ablynx. And according to Christian Kanstrup, SVP Biopharm operations, the Danish corporation is not planning to cease its acquisitions afterwards.
BY MARTIN HAVTORN PETERSEN
During the past month, Novo Nordisk has worked to acquire the Belgian biotech company Ablynx for a sum amounting to more than DKK 20 billion (USD 3.22 billion).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Here is Novo Nordisk’s strategy for the future
For abonnenter
Novo Nordisk enters partnership with Belgian company
For abonnenter
